Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px
Document › Details

OrbiMed Advisors LLC. (10/24/23). "Press Release: OrbiMed Raises $4.3 Billion Across Private Investment Funds". New York, NY.

Organisations Organisation OrbiMed Private Investments IX fund
  Group OrbiMed (Group)
  Organisation 2 OrbiMed Royalty & Credit Opportunities IV fund
  Group OrbiMed (Group)
Products Product investment management
  Product 2 healthcare
Person Person Neild, Carter (OrbiMed 202310 Managing Partner=
     


OrbiMed, a global healthcare investment firm, is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.

Consistent with their predecessors, these new funds enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities. OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.

OrbiMed is led by its 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance. The firm’s professionals are based in a dozen global locations across key healthcare markets in North America, Europe and Asia.

Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.

“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds,” said Carter Neild, a Managing Partner of OrbiMed. “We will endeavor to meet our partners’ high expectations in the coming years.”


About OrbiMed

OrbiMed is a leading healthcare investment firm with more than $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of more than 130 professionals is based in New York City; London; San Francisco; Shanghai; Hong Kong; Mumbai, India; Herzliya, Israel; and other key global markets. For more information, please visit www.orbimed.com. Follow us on X (formerly Twitter) @OrbiMed.


Media Contacts:

Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com

Erin Bocherer
Phone: (678) 294-2258
Cogenta Communications for OrbiMed
Email: Erin@cogentacom.com

   
Record changed: 2024-01-06

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for OrbiMed (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x300px




» top